“We intend to serve detail later this year for our plans for a Phase III program.”

In context

“r. We also continue to strengthen our portfolio by harnessing external innovation through strategic business development. The recent closing of our global ex China in-licensing agreement with 3SBio grants has exclusive rights to develop, manufacture and commercialize SSGJ-707, a bispecific antibody. Targeting PD-1 and VEGF has the potential to deliver breakthroughs for patients in the next wave in PD-1 immunotherapy, which is an established $55 billion market. With comparing monotherapy data in advanced non-small cell lung cancer presented recently at ASCO. We view this promising cancer immunotherapy candidate as a seamless fit within Pfizer's oncology strategy. Given our deep experience in the development of antibody therapeutics and our differentiated industry-leading portfolio of ADCs. We intend to serve detail later this year for our plans for a Phase III program. With Pfizer's established presence and global reach, we believe 707 has the potential to become a backbone therapy for multiple solid tumor types where the PD-L1/VEGF mechanism could have significant impact. Across our pipeline, we continue to sharpen our focus on programs where the strength of our capabilities give us the greatest opportunities to address substantial patient need. We look forward to sharing future updates about our progress. Now let's move to commercial. Our commercial strategy is unlocking higher productivity and performance across both our U.S. and international divisions. With several of our established brands, we are pleased with our continued market leadership and growth. We delivered another solid quarter for our Vyndaqel family, with 21% year-over-year operational”